Oligonucleotide sequences targeting transcription factor TSC22D4 for the treatment of insulin resistance

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10676739
APP PUB NO 20180023078A1
SERIAL NO

15545104

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to oligonucleotide inhibitors of the TSC22D4 activity or expression and their uses for the prevention, treatment, and/or regulation of insulin resistance, metabolic syndrome and/or diabetes and/or for improving insulin sensitivity in a mammal.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTSIM NEUENHEIMER FELD 280 HEIDELBERG 69120

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Berriel, Diaz Mauricio Dossenheim, DE 5 5
Herzig, Stephan Vaterstetten, DE 8 20
Schafmeier, Tobias Mannheim, DE 4 0

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Dec 9, 2027
11.5 Year Payment $7400.00 $3700.00 $1850.00 Dec 9, 2031
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00